The oligonucleotide CDMO market is expected to grow, with forecasts suggesting it may reach various values by different years, including USD 6.73 billion by 2029. Other related markets, such as the oligonucleotides market and cell and gene therapy CDMO market, are also predicted to experience significant growth, potentially reaching USD 16.10 billion and USD 125.09 billion by 2035, respectively. The exact size and growth of the oligonucleotide CDMO market is unclear, with different reports providing varying estimates and projections.